Japanese Journal of Ophthalmology

, Volume 57, Issue 1, pp 68–73 | Cite as

Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration

  • Chikako Yoshizawa
  • Wataru SaitoEmail author
  • Shigeki Hirose
  • Hirokuni Kitamei
  • Kousuke Noda
  • Susumu Ishida
Clinical Investigation



To report the results of triple therapy with photodynamic therapy (PDT) (PDT combined with intravitreal injection of bevacizumab (IVB) and sub-tenon injection of triamcinolone acetonide (STTA)) for the treatment of age-related macular degeneration (AMD) in Japanese patients.


This retrospective case series included 38 eyes of 38 patients with exudative AMD treated with PDT combined with IVB (1.25 mg) and STTA (40 mg). Retreatment was performed in the same manner with intervals of at least 3 months. All patients had been treatment naïve, with a follow-up period of 12 months. Best-corrected visual acuity (BCVA), macular retinal thickness (MRT) on optical coherence tomography, and the number of treatments were analyzed.


The mean logarithm of the minimum angle of resolution BCVA in patients treated with PDT triple therapy was 0.86 ± 0.55 at baseline and 0.62 ± 0.55 at 12 months (p < 0.001). The mean MRT was 554.0 ± 202.6 μm at baseline and 205.1 ± 78.6 μm at 12 months (p < 0.001). During the 1-year follow-up, the average number of PDT triple therapy (treatments per patient) was 1.1. No complications, for example increase in intraocular pressure, cataract, or endophthalmitis, were observed.


In AMD patients, PDT triple therapy significantly improved visual acuity with a minimum number of treatments and a low risk of complications during the 1-year follow-up.


Age-related macular degeneration Photodynamic therapy Bevacizumab Sub-tenon injection Triamcinolone acetonide 


  1. 1.
    Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835–44.PubMedGoogle Scholar
  2. 2.
    Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year Anchor results. Am J Ophthalmol. 2007;144:850–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the Marina study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868–75.PubMedCrossRefGoogle Scholar
  4. 4.
    Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the Marina study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009;116:362.PubMedCrossRefGoogle Scholar
  6. 6.
    Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina. 2009;29:133–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina. 2006;26:602–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Tano Y. Guidelines for PDT in Japan. Ophthalmology. 2008;115(585–585):e6.PubMedGoogle Scholar
  9. 9.
    Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology. 2003;110:1306–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ. Triamcinolone stimulates bFGF production and inhibits TGF-β1 production by human dermal fibroblasts. Dermatol Surg. 2002;28:704–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46:1440–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:2743–9.PubMedCrossRefGoogle Scholar
  13. 13.
    CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.PubMedCrossRefGoogle Scholar
  14. 14.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol. 2007;7:10.PubMedCrossRefGoogle Scholar
  15. 15.
    Shirakata Y, Shiragami C, Yamashita A, Nitta E, Fujiwara A, Shiraga F. One-year results of intravitreal bevacizumab and posterior subtenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol. (in press).Google Scholar
  16. 16.
    Kovacs KD, Quirk MT, Kinoshita T, Gautam S, Ceron OM, Murtha TJ, et al. A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon’s triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. Retina. 2010;31:446–52.CrossRefGoogle Scholar
  17. 17.
    Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand. 2005;83:645–63.PubMedCrossRefGoogle Scholar
  18. 18.
    Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol. 2008;19:208–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Honda S, Kurimoto Y, Kagotani Y, Yamamoto H, Takagi H, Uenishi M. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol. 2009;53:593–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Saito K, Yamamoto T, Tsuchiya D, Kawasaki R, Haneda S, Yamashita H. Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration. Jpn J Ophthalmol. 2009;53:512–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;150(48–54):e1.PubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2012

Authors and Affiliations

  • Chikako Yoshizawa
    • 1
  • Wataru Saito
    • 1
    Email author
  • Shigeki Hirose
    • 1
  • Hirokuni Kitamei
    • 1
  • Kousuke Noda
    • 1
  • Susumu Ishida
    • 1
  1. 1.Department of OphthalmologyHokkaido University Graduate School of MedicineSapporoJapan

Personalised recommendations